BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37671354)

  • 1. Construction and validation of a PANoptosis-related lncRNA signature for predicting prognosis and targeted drug response in thyroid cancer.
    Li R; Zhao M; Sun M; Miao C; Lu J
    PeerJ; 2023; 11():e15884. PubMed ID: 37671354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prognostic signature of pyroptosis-related lncRNAs verified in gastric cancer samples to predict the immunotherapy and chemotherapy drug sensitivity.
    Wang Y; Chen X; Jiang F; Shen Y; Fang F; Li Q; Yang C; Dong Y; Shen X
    Front Genet; 2022; 13():939439. PubMed ID: 36147488
    [No Abstract]   [Full Text] [Related]  

  • 3. A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer.
    Wang L; Xiao K; Dong Z; Meng T; Cheng X; Xu Y
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10543-10559. PubMed ID: 37291405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy.
    Hong K; Cen K; Chen Q; Dai Y; Mai Y; Guo Y
    Front Immunol; 2023; 14():1128390. PubMed ID: 36761753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
    Li L; Xie R; Lu G
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma.
    Qin Y; Zhang D; Zhang H; Hou L; Wang Z; Yang L; Zhang M; Zhao G; Yao Q; Ling R; Zhang J
    Cancer Cell Int; 2022 Sep; 22(1):296. PubMed ID: 36175889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PANoptosis-related long non-coding RNA signature to predict the prognosis and immune landscapes of pancreatic adenocarcinoma.
    Zhao Q; Ye Y; Zhang Q; Wu Y; Wang G; Gui Z; Zhang M
    Biochem Biophys Rep; 2024 Mar; 37():101600. PubMed ID: 38371527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer.
    Yang M; Sun Y; Ji H; Zhang Q
    Ann Transl Med; 2022 Dec; 10(24):1399. PubMed ID: 36660659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
    Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
    Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a pyroptosis-related lncRNAs signature for predicting prognosis and immunotherapy response in glioma.
    Huang Q; Yan J; Jiang Q; Guo F; Mo L; Deng T
    Medicine (Baltimore); 2023 Feb; 102(6):e32793. PubMed ID: 36820554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
    Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
    Front Immunol; 2022; 13():919231. PubMed ID: 35967366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of m6A-associated LncRNAs as predict factors for the immune infiltration and prognosis of thyroid cancer.
    Su Y; Xu B; Li J; Shen Q; Lei Z; Ma M; Zhang F; Hu T
    Ann Med; 2023 Dec; 55(1):1298-1316. PubMed ID: 36974635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel PANoptosis-related long non-coding RNA index to predict prognosis, immune microenvironment and personalised treatment in hepatocellular carcinoma.
    Wang L; Wan P; Xu Z
    Aging (Albany NY); 2024 Jan; 16(3):2410-2437. PubMed ID: 38284890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Ferroptosis-Associated Long Noncoding RNA Prognostic Model and Tumor Immune Microenvironment in Thyroid Cancer.
    Lin Y; Gan F; He X; Deng H; Li Y
    J Immunol Res; 2022; 2022():5893998. PubMed ID: 35915656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction and Validation of a Novel Pyroptosis-Related Four-lncRNA Prognostic Signature Related to Gastric Cancer and Immune Infiltration.
    Wang Z; Cao L; Zhou S; Lyu J; Gao Y; Yang R
    Front Immunol; 2022; 13():854785. PubMed ID: 35392086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.